Speakers
Amr Abdeen
Postdoctoral Associate
University of Wisconsin- Madison
Discussion Day
2:00 pm | Improved Non-Viral Vectors for In Vivo Genome Editing
Omar Abudayyeh
McGovern Fellow
Harvard University
Day Two
Thursday May 21 2020
8:30 am | Harnessing Novel CRISPR Tools for Genome Engineering and RNA Editing
Alejandro Amador
Head of High Throughput Biology, Functional Genomics
GlaxoSmithKline
Andrew Anzalone
Postdoctoral Fellow
Liu Group, Broad Institute
Day One
Wednesday May 21 2020
8:30 am | Exploring the Potential of Prime Editing
Luis Barrera
Head of Computational Sciences
Beam Therapeutics
Day Two
Thursday May 21 2020
1:30 pm | Comprehensive Identification of Base Editor Off-Targets in the Context of Therapeutically Relevant Delivery
12:00 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?
Carsten Charlesworth
Graduate
Stanford University
Day Two
Thursday May 21 2020
4:00 pm | Utilizing CRISPR to Grow Human Organs for Transplantation
Delai Chen
Associate Director, Nanoparticle Formulation
Beam Therapeutics
Discussion Day
12:15 pm |
Paul Diehl
Chief Operating Officer
Cellecta
Day One
Wednesday May 21 2020
11:30 am | Functional CRISPR Screening and Cell Barcoding to Identify Genes Driving Biological Responses and Disease Progression
Rafi Emmanuel
Research Director
Emendo Biotherapeutics
Day One
Wednesday May 21 2020
2:30 pm | Target Optimized Variant of CRISPR Associated Nuclease Enables Allele-Specific Knock Out of ELANE-Related Neutropenia
Jonathan Gootenberg
McGovern Fellow
Harvard University
Day Two
Thursday May 21 2020
10:30 am | CRISPR Diagnostics: Expanding the Nucleic Acid Detection Toolbox by Harnessing Microbial Diversity
Julian Grunewald
Research Fellow
Joung Lab, Massachusetts General
Day One
Wednesday May 21 2020
9:00 am | Developing and Improving Base Editors
Killian Hanlon
Research Fellow
Harvard University
Discussion Day
10:15 am | Overcoming Limitations of Viral Vectors to Deliver CRISPR Machinery
Ben Kleinstiver
Principal Investigator
Massachusetts General
Day Two
Thursday May 21 2020
11:30 am | Broadly Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties
Sanne Klompe
Graduate
Sternerg Lab, Columbia University
Day One
Wednesday May 21 2020
11:00 am | Utilizing CRISPR-Associated Transposons for Programmed Insertions Without Generating Double-Strand Breaks
Kunwoo Lee
Chief Executive Officer & Co-Founder
GenEdit
Discussion Day
12:15 pm |
11:45 am | Non-Viral Delivery of CRISPR Using Polymer Nanoparticles
Blair Madison
Senior Director, Genetic Engineering
Poseida Therapeutics
Day Two
Thursday May 21 2020
2:00 pm | Creating Novel Proteins to Optimize Efficacy and Specificity
12:00 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?
Ana Moreno
Founder & Chief Executive Officer
Navega Therapeutics
Day Two
Thursday May 21 2020
9:00 am | Epigenome Editing using CRISPR to Treat Pain
Niren Murthy
Professor
University of California at Berkeley
Discussion Day
11:15 am | Gene Editing After Local Injection: Non-Viral Delivery
Kiran Musunuru
Principal Investigator
Harvard University
Day Two
Thursday May 21 2020
2:30 pm | Applying CRISPR to Predict and Treat Cardiovascular Disease
Kalina Paunovska
Postdoctoral Fellow
Dahlman Lab, Georgia Tech
Discussion Day
2:30 pm | Delivering CRISPR Apparatus In Vivo Using Nanoparticle Technology
Karl Petri
Research Fellow
Joung Lab, Massachusetts General
Day One
Wednesday May 21 2020
3:30 pm | ONE-seq: Detection of CRISPR Nuclease and Base Editor Off-Targets with Ultra-High Sensitivity to Ensure the Safety of CRISPR Therapeutics
Sicco Popma
Founder, Chief Executive Officer & President
IO Biosciences
Day Two
Thursday May 21 2020
3:30 pm | Developing CRISPR-Based Cell Therapies Using a Proprietary Gene Editing System (GEMS)
Satinder Rawat
Senior Licensing Officer
University of Massachusetts
Day One
Wednesday May 21 2020
2:00 pm | Bridging the Gap Between Academia and Industry: Translating Cutting-Edge Technologies from the Lab to the Clinic
David Schaffer
Co-Founder
4D Molecular Therapeutics
Discussion Day
9:45 am | Directed Evolution of Novel AAV Variants for Clinical Gene Therapy
Brett Staahl
Founder & Head of Applied Technologies
Scribe Therapeutics
Discussion Day
9:15 am | Why Isn’t the Future of Medicine Here Yet?
Marija Tadin- Strapps
Vice President, Exploratory Biology
SQZ Biotechnologies
Discussion Day
3:00 pm | CellSQZ platform for Development of Next Generation Cell Therapies
Fyodor Urnov
Scientific Director
Innovative Genomics Institute
Day One
Wednesday May 21 2020
4:30 pm | Chair’s Closing Remarks
8:00 am | KEYNOTE: CRISPR 2030: the Promise and the Challenge
7:50 am | Chair’s Opening Remarks
Rui Wang
Principal Research Scientist
Abbvie
Renee Wegrzyn
Program Manager
DARPA
Day Two
Thursday May 21 2020
11:00 am | Programmable Gene Modulation
Carlo Zambonelli
Associate Director
Beam Therapeutics
Day One
Wednesday May 21 2020
4:00 pm | Developing Assays and Tools for Base Editing
Kate Zhang
Vice President, Biological Development
Editas Medicine
Day One
Wednesday May 21 2020
11:50 am | Optimizing CRISPR/Cas to Translate Efficiently into the Clinic
Lihua Julie Zhu
Professor & Head of Bioinformatics Core
University of Massachusetts
Speaker to be Confirmed
Aldevron
Day One
Wednesday May 21 2020